OTCMKTS:BIOVF Swedish Orphan Biovitrum (BIOVF) Stock Price, News & Analysis $28.97 -0.82 (-2.75%) As of 08/12/2025 03:29 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort InterestBuy This Stock About Swedish Orphan Biovitrum Stock (OTCMKTS:BIOVF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BIOVF alerts:Sign Up Key Stats Today's Range$28.94▼$28.9750-Day Range$27.06▼$31.9952-Week Range$25.80▼$32.25Volume500 shsAverage Volume54 shsMarket Capitalization$10.31 billionP/E Ratio24.34Dividend YieldN/APrice TargetN/AConsensus RatingStrong Buy Company Overview Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden. Read More Receive BIOVF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Swedish Orphan Biovitrum and its competitors with MarketBeat's FREE daily newsletter. Email Address BIOVF Stock News HeadlinesSwedish Orphan Biovitrum AB (BIOVF) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ...July 19, 2025 | finance.yahoo.comSwedish Orphan Biovitrum AB (publ) (BIOVF) Q2 2025 Earnings Call TranscriptJuly 16, 2025 | seekingalpha.comHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.August 14 at 2:00 AM | Paradigm Press (Ad)Swedish Orphan Biovitrum AB Non-GAAP EPS of SEK 2.36, revenue of SEK 6.17B; reaffirms FY25 outlookJuly 16, 2025 | seekingalpha.comSwedish Orphan Biovitrum AB (BIOVF) Reports Strong Q2 Revenue GrowthJuly 16, 2025 | gurufocus.comSobi Board Approves Share Repurchase for Incentive ProgramJuly 15, 2025 | tipranks.comSobi and Apellis Amend Royalty Agreement for AspaveliJuly 1, 2025 | tipranks.comSwedish Orphan Biovitrum: Haematology Focus Seems To Be Paying OffMay 21, 2025 | seekingalpha.comSee More Headlines BIOVF Stock Analysis - Frequently Asked Questions How have BIOVF shares performed this year? Swedish Orphan Biovitrum's stock was trading at $27.66 at the beginning of the year. Since then, BIOVF stock has increased by 4.7% and is now trading at $28.97. How were Swedish Orphan Biovitrum's earnings last quarter? Swedish Orphan Biovitrum (OTCMKTS:BIOVF) posted its earnings results on Wednesday, July, 16th. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.18 by $0.06. The company earned $649.61 million during the quarter, compared to analyst estimates of $644.68 million. Swedish Orphan Biovitrum had a net margin of 16.05% and a trailing twelve-month return on equity of 11.67%. How do I buy shares of Swedish Orphan Biovitrum? Shares of BIOVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings7/16/2025Today8/14/2025Next Earnings (Estimated)10/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryN/A Current SymbolOTCMKTS:BIOVF CIKN/A Webwww.sobi.com Phone(468) 697-2000FaxN/AEmployees1,937Year Founded2001Profitability EPS (Trailing Twelve Months)$1.19 Trailing P/E Ratio24.34 Forward P/E RatioN/A P/E GrowthN/ANet Income$367.52 million Net Margins16.05% Pretax Margin18.72% Return on Equity11.67% Return on Assets6.34% Debt Debt-to-Equity Ratio0.22 Current Ratio1.00 Quick Ratio0.66 Sales & Book Value Annual Sales$2.46 billion Price / Sales4.19 Cash Flow$2.05 per share Price / Cash Flow14.12 Book Value$11.36 per share Price / Book2.55Miscellaneous Outstanding Shares356,000,000Free FloatN/AMarket Cap$10.31 billion OptionableNot Optionable Beta0.46 Social Links 10 Stocks Set to Soar in Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (OTCMKTS:BIOVF) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredGet This Stock NowThis company is the lifeblood of AI data centers, yet almost no one has caught up with the story. Their hardwa...InvestorPlace | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Swedish Orphan Biovitrum Please log in to your account or sign up in order to add this asset to your watchlist. Share Swedish Orphan Biovitrum With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.